Literature DB >> 17894849

IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease.

Rebecca L Roberts1, Richard B Gearry, Jade E Hollis-Moffatt, Allison L Miller, Julia Reid, Victor Abkevich, Kirsten M Timms, Alexander Gutin, Jerry S Lanchbury, Tony R Merriman, Murray L Barclay, Martin A Kennedy.   

Abstract

OBJECTIVE: Recently, separate genome-wide association analyses have identified nonsynonymous SNPs in IL23R and ATG16L1 (rs11209026; c1142G>A, R381Q, and rs2241880; c1338A>G, T300A, respectively) as strong candidate susceptibility factors for Crohn's disease (CD) in whites. The aim of our study was to test whether these SNPs are associated with CD in a population-based cohort of New Zealand Caucasian inflammatory bowel disease (IBD) patients.
METHODS: Allele frequencies of rs11209026 and rs2241880 were determined in 496 CD patients, 466 ulcerative colitis (UC) patients, and 591 controls. Distribution of the relevant alleles was compared between controls and IBD patients. rs11209026 and rs2241880 genotype distributions were examined both within IBD clinical subphenotypes and CARD15 genotypes.
RESULTS: rs11209026 and rs2241880 were both associated with CD (P valuers11209026=0.0026, OR 0.54, 95% CI 0.36-0.81; P valuers2241880=0.0001, OR 1.41, 95% CI 1.18-1.67). In addition, there was evidence for association of rs11209026 with UC (P value=0.037, OR 0.66, 95% CI 0.45-0.98). No significant association was observed between IL23R genotype or ATG16L1 genotype and IBD subphenotypes. IL23R was associated with CD and UC only in the absence of CARD15 mutations, whereas ATG16L1 was associated with CD in the presence and absence of CARD15 mutations.
CONCLUSIONS: We replicated the previously reported associations between CD and rs11209026 and rs2241880, confirming that IL23R and ATG16L1 are susceptibility loci for CD in the New Zealand population. We also provide further evidence for association of rs11209026 with UC and a report of an additive effect between IL23R and CARD15 genotypes in CD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894849     DOI: 10.1111/j.1572-0241.2007.01525.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  45 in total

1.  Interaction between CTLA4 gene and IBD5 locus in Hungarian Crohn's disease patients.

Authors:  Veronika Csöngei; Luca Járomi; Eniko Sáfrány; Csilla Sipeky; Lili Magyari; Noémi Polgár; Judit Bene; Patrícia Sarlós; Lilla Lakner; Eszter Baricza; Melinda Szabó; Gábor Rappai; Béla Melegh
Journal:  Int J Colorectal Dis       Date:  2011-04-26       Impact factor: 2.571

2.  Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions.

Authors:  Toshihiko Okazaki; Ming-Hsi Wang; Patricia Rawsthorne; Michael Sargent; Lisa Wu Datta; Yin Yao Shugart; Charles N Bernstein; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2008-11       Impact factor: 5.325

3.  Contribution of rs11465788 in IL23R gene to Crohn's disease susceptibility and phenotype in Chinese population.

Authors:  Chen Bin; Zeng Zhirong; Wu Xiaoqin; Chen Minhu; Li Mei; Gao Xiang; Chen Baili; Hu Pinjin
Journal:  J Genet       Date:  2009-08       Impact factor: 1.166

4.  IL23R haplotypes provide a large population attributable risk for Crohn's disease.

Authors:  Kent D Taylor; Stephan R Targan; Ling Mei; Andrew F Ippoliti; Dermot McGovern; Emebet Mengesha; Lily King; Jerome I Rotter
Journal:  Inflamm Bowel Dis       Date:  2008-09       Impact factor: 5.325

Review 5.  ATG16L1: A multifunctional susceptibility factor in Crohn disease.

Authors:  Mohammad Salem; Mette Ammitzboell; Kris Nys; Jakob Benedict Seidelin; Ole Haagen Nielsen
Journal:  Autophagy       Date:  2015-04-03       Impact factor: 16.016

6.  Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease.

Authors:  Dermot P B McGovern; Jerome I Rotter; Ling Mei; Talin Haritunians; Carol Landers; Carrie Derkowski; Deb Dutridge; Marla Dubinsky; Andy Ippoliti; Eric Vasiliauskas; Emebet Mengesha; Lily King; Sheila Pressman; Stephan R Targan; Kent D Taylor
Journal:  Inflamm Bowel Dis       Date:  2009-06       Impact factor: 5.325

7.  Genetic association of nonsynonymous variants of the IL23R with familial and sporadic inflammatory bowel disease in women.

Authors:  Zhenwu Lin; Lisa Poritz; Andre Franke; Tong-Yi Li; Andreas Ruether; Kathryn A Byrnes; Yunhua Wang; Anthony W Gebhard; Colin MacNeill; Neal J Thomas; Stefan Schreiber; Walter A Koltun
Journal:  Dig Dis Sci       Date:  2009-03-18       Impact factor: 3.199

8.  Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand caucasian population.

Authors:  Lynnette R Ferguson; Dug Yeo Han; Claudia Huebner; Ivonne Petermann; Murray L Barclay; Richard B Gearry; Alan McCulloch; Pieter S Demmers
Journal:  Gastroenterol Res Pract       Date:  2009-05-03       Impact factor: 2.260

9.  The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease.

Authors:  Ondrej Hradsky; Petra Dusatkova; Martin Lenicek; Jiri Bronsky; Jiri Nevoral; Libor Vitek; Milan Lukas; Ivana Zeniskova; Ondrej Cinek
Journal:  BMC Med Genet       Date:  2010-06-10       Impact factor: 2.103

10.  IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease.

Authors:  Elisabet Einarsdottir; Lotta L E Koskinen; Emma Dukes; Kati Kainu; Sari Suomela; Maarit Lappalainen; Fabiana Ziberna; Ilma R Korponay-Szabo; Kalle Kurppa; Katri Kaukinen; Róza Adány; Zsuzsa Pocsai; György Széles; Martti Färkkilä; Ulla Turunen; Leena Halme; Paulina Paavola-Sakki; Tarcisio Not; Serena Vatta; Alessandro Ventura; Robert Löfberg; Leif Torkvist; Francesca Bresso; Jonas Halfvarson; Markku Mäki; Kimmo Kontula; Ulpu Saarialho-Kere; Juha Kere; Mauro D'Amato; Päivi Saavalainen
Journal:  BMC Med Genet       Date:  2009-01-28       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.